

**CA OPIOID SETTLEMENTS**  
**EXPENDITURE REPORTING FORM**

**SFY 2023 - 2024**

**Prepared on 2025-12-04 by the University of  
California, Los Angeles**

**Integrated Substance Use and Addictions Programs**



# CONTENTS

GENERAL INFORMATION	1
CA ABATEMENT ACCOUNT FUNDS INFORMATION	1
CA Abatement Payments: . . . . .	1
CA Abatement Reallocations: . . . . .	2
CA Abatement Expenditures: . . . . .	2
Activity#1 . . . . .	2
CA SUBDIVISION FUND INFORMATION	3
CA Subdivision Fund Payments: . . . . .	4
CA Subdivision Fund Reallocations: . . . . .	4
CA Subdivision Fund Future Opioid-Related Expenditures: . . . . .	5
Activity#1 . . . . .	5
CA Subdivision Fund Reimbursements & Past Legal Expenses: . . . . .	5
MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION	6
Mallinckrodt Bankruptcy Payments: . . . . .	6
Mallinckrodt Reallocations: . . . . .	6
Mallinckrodt Allowable Expenses: . . . . .	6
SUMMARY	6

# GENERAL INFORMATION

**Participating Subdivision:** Mariposa County  
**Subdivision Department/Organization:** Health and Human Services Agency  
**Subdivision address:** P.O. Box 99 Mariposa California 95338  
**Name of Preparer:** Randy Ridenhour  
**Preparer Title:** Sr. Administrative Analyst  
**Preparer Email Address:** rridenhour@mariposacounty.org  
**Preparer Phone Number:** 209-742-0922  
**This Subdivision received funds from:**  
Settlements & Mallinckrodt Pharmaceuticals Bankruptcy

# CA ABATEMENT ACCOUNT FUNDS INFORMATION

- Settlement(s):**
- Distributors (McKesson, Cardinal Health and Cencora, previously Amerisource Bergen)
  - Janssen Pharmaceuticals, Inc.

## CA Abatement Payments:

Payments Received by this Subdivision from the CA Abatement Account Fund

Settlement	CA Abatement Account Payments Received in SFY 23-24
Distributors	\$64,176.40
Janssen	\$28,994.30

---

**Is your Participating Subdivision depositing CA Abatement Accounts Fund payments from the National Settlement Administrator (Brown-Greer, PLC) into an interest-bearing account?:** Yes

Interest Earned from the CA Abatement Account Fund

Settlement	CA Abatement Account Interest Earned in SFY 23-24
Distributors	\$3,645.19
Janssen	\$2,423.09

### CA Abatement Reallocations:

**Reallocations Sent:** No funds received from the CA Abatement Account were reallocated to another Subdivision.

**Reallocations Received:** No funds received from the CA Abatement Account were reallocated from another Subdivision.

### CA Abatement Expenditures:

**How many total activities or programs funded by the funds from the CA Abatement Accounts Fund will you be reporting on for the SFY 23-24 (period of July 1, 2023 - June 30, 2024)?:** 1

#### Activity#1

**Activity or Program Name:** TREATMENT FOR INCARCERATED POPULATION

**Activity or Program Description:** F. TREATMENT FOR INCARCERATED POPULATION 1. Provide evidence-based treatment and recovery support, including MAT for persons with OUD and co-occurring SUD/MH disorders within and transitioning out of the criminal justice system;

## Activity Costs and Encumbered Funds

Settlement	Direct Costs in SFY 23-24	Indirect Costs (Admin. Expenses) in SFY 23-24	Funds Encumbered in SFY 23-24
Distributors	\$0.00	\$0.00	\$0.00
Janssen	\$33,768.16	\$0.00	\$0.00

**Did you previously encumber funds for this activity in SFY 22-23 that were not expended in SFY 23-24?:** No

**Activity Start Date (mm/dd/yyyy):** 07/01/2023

**All local agencies or organizations who were given funds during SFY 23-24 to implement this activity:**

Mariposa County Health and Human Services Agency

**Allowable Expenditure Category:** Address the Needs of Criminal Justice-Involved Persons

High Impact Abatement Activity (HIAA) Category

HIAA Satisfied	Reasoning
<b>HIAA 2:</b> Creating new or expanded Substance Use Disorder (SUD) treatment infrastructure Please describe:	Expansion of MAT for persons with OUD and co-occurring SUD/MH disorders within and transitioning out of the criminal justice system. The FY23-24 expenditures \$33,768.16 were for MAT medications.

## CA SUBDIVISION FUND INFORMATION

**Is your Participating Subdivision also a Plaintiff Subdivision?:** Yes

- Distributors (McKesson, Cardinal Health and Cencora, previously Amerisource Bergen)
- Janssen Pharmaceuticals, Inc.

## CA Subdivision Fund Payments:

Payments Received by this Plaintiff Subdivision from the CA Subdivision Fund

Settlement	CA Subdivision Fund Payments Received in SFY 23-24
Distributors	\$14,393.19
Janssen	\$6,502.70

**Is your Participating Subdivision depositing CA Subdivision Fund payments from the National Settlement Administrator (BrownGreer, PLC) into an interest-bearing account?:** Yes

Interest Earned from the CA Subdivision Fund

Settlement	CA Subdivision Fund Interest Earned in SFY 23-24
Distributors	\$817.53
Janssen	\$543.44

## CA Subdivision Fund Reallocations:

**Reallocations Sent:** No funds received from the CA Subdivision Fund were reallocated to another Subdivision.

**Reallocations Received:** No funds received from the CA Subdivision Fund were reallocated from another Subdivision.

## CA Subdivision Fund Future Opioid-Related Expenditures:

How many total activities or programs were funded by funds from the CA Subdivision Fund will you be reporting on for the SFY 23-24 (period of July 1, 2023 - June 30, 2024)?: 1

### Activity#1

**Activity or Program Name:** TREATMENT FOR INCARCERATED POPULATION

**Activity or Program Description:** TREATMENT FOR INCARCERATED POPULATION 1. Provide evidence-based treatment and recovery support, including MAT for persons with OUD and co-occurring SUD/MH disorders within and transitioning out of the criminal justice system; FY23-24 expenditures were for MAT medications direct costs.

Activity Expenditures

Settlement	Funds Expended (SFY 23-24)
Distributors	\$3,715.91
Janssen	\$2,470.09

**Allowable Expenditure Category:**

2 – Treat or mitigate opioid use or related disorders.

## CA Subdivision Fund Reimbursements & Past Legal Expenses:

**During SFY 23-24, did your Plaintiff Subdivision use settlement funds to cover past legal expenses related to opioid litigation?:** No

**During SFY 23-24, did your Plaintiff Subdivision use settlement funds to cover reimbursements for past opioid-related expenses spent prior to the receipt of settlement funds?:** No

# MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION

**Did your Local Government receive funds from the Mallinckrodt Bankruptcy (NOAT II)?:** Yes

## Mallinckrodt Bankruptcy Payments:

**Total amount of funds received from NOAT II from July 1, 2023 – June 30, 2024:**

\$8,953.03

**Is your Local Government depositing Mallinckrodt Bankruptcy payments from NOAT II into an interest-bearing account?**

No

## Mallinckrodt Reallocations:

### Reallocations Sent:

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated to another Subdivision.

### Reallocations Received:

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated from another Subdivision.

## Mallinckrodt Allowable Expenses:

**Did your Local Government expend any bankruptcy funds during the period of July 1, 2023 – June 30, 2024?:** No

# SUMMARY

**All tables below are based on information reported during the SFY 2023-24 only.**

### CA Abatement Account Fund Totals

<b>Settlement</b>	<b>Payment</b>	<b>Interest</b>	<b>Reallocations Sent</b>	<b>Reallocations Received</b>
Distributors	\$64,176.40	\$3,645.19	\$0.00	\$0.00
Janssen	\$28,994.30	\$2,423.09	\$0.00	\$0.00
<b>Total</b>	<b>\$93,170.70</b>	<b>\$6,068.28</b>	<b>\$0.00</b>	<b>\$0.00</b>

### CA Abatement Account Activity Expenses

<b>Settlement</b>	<b>Activity Expenses</b>	<b>Indirect Costs</b>	<b>23/24 Encumbered Funds</b>	<b>22/23 Encumbered Funds</b>
Distributors	\$0.00	\$0.00	\$0.00	\$0.00
Janssen	\$33,768.16	\$0.00	\$0.00	\$0.00
<b>Total</b>	<b>\$33,768.16</b>	<b>\$0.00</b>	<b>\$0.00</b>	<b>\$0.00</b>

### CA Subdivision Fund Totals

<b>Settlement</b>	<b>Payment</b>	<b>Interest</b>	<b>Reallocation Sent</b>	<b>Reallocation Received</b>
Distributors	\$14,393.19	\$817.53	\$0.00	\$0.00
Janssen	\$6,502.70	\$543.44	\$0.00	\$0.00
<b>Total</b>	<b>\$20,895.89</b>	<b>\$1,360.97</b>	<b>\$0.00</b>	<b>\$0.00</b>

CA Subdivision Fund Expenses

<b>Settlement</b>	<b>Activity Expense</b>	<b>Legal Expenses</b>	<b>Reimbursed Activity Expense</b>
Distributors	\$3,715.91	\$0.00	\$0.00
Janssen	\$2,470.09	\$0.00	\$0.00
Total	\$6,186.00	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Totals

<b>Payment</b>	<b>Interest</b>	<b>Reallocations Sent</b>	<b>Reallocations Received</b>
\$8,953.03	\$0.00	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Expenses

<b>Direct Costs</b>	<b>Indirect Costs</b>
\$0.00	\$0.00